Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Stoke Therapeutics adds Alexander Cumbo to board after Kaye resignationSep 25PeopleStoke Therapeutics, Inc
Stoke Therapeutics files $200 million at-the-market stock offeringAug 3FinancingStoke Therapeutics, Inc
Stoke reports full EMPEROR enrollment, sets pre-NDA meeting and Q1 2027 filing startAug 3Quarterly updateStoke Therapeutics, Inc
Stoke Therapeutics completes enrollment of 162-patient Phase 3 EMPEROR trial for zorevunersenJun 30Trial updateStoke Therapeutics, Inczorevunersen